NLS Pharmaceutics AG
NASDAQ: NLSP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alexander Zwyer
- Employees
- 6
- Headquarters
- Zurich, Switzerland
- IPO year
- 2021
- Market cap
- $919.6K
- Website
- https://nlspharma.com
Loading NLSP…
Loading profile data…Frequently asked questions about NLSP
What does NLS Pharmaceutics AG (NLSP) do?
NLS Pharmaceutics AG is a biopharmaceutical firm dedicated to researching and creating treatments for intricate and uncommon conditions affecting the central nervous system. Its primary focus includes advancing medications for narcolepsy, idiopathic hypersomnia, and various other unusual sleep conditions, alongside neurodevelopmental challenges...
Where does NLSP trade?
NLS Pharmaceutics AG (NLSP) trades on the NASDAQ Capital Market.
What sector is NLSP in?
NLS Pharmaceutics AG (NLSP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NLS Pharmaceutics AG?
Alexander Zwyer is the chief executive officer of NLS Pharmaceutics AG (NLSP).
Where is NLS Pharmaceutics AG headquartered?
NLS Pharmaceutics AG is headquartered in Switzerland.
Does NLSP pay a dividend?
NLS Pharmaceutics AG (NLSP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NLSP go public?
NLS Pharmaceutics AG (NLSP) completed its initial public offering in 2021.